Psychiatry and Neurology, Neurology · West Columbia, SC
NPI
1720099005
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
146 E Hospital Dr Ste 120a
West Columbia, SC, 29169
Phone (803) 936-7076
Groups this clinician bills Medicare through
Medicare paid, 2024
$195K
13,426 services
Medicare patients, 2024
917
Average age 75
Drug cost, 2024
$1.1M
2,929 prescriptions
Company payments, 2025
$2,118
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark K Lencke was code J0585 (injection, onabotulinumtoxina, 1 unit), 11,745 times for 24 patients. In total Mark K Lencke billed 13,426 services in 24 codes, and Medicare paid $195K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 11,745 | 24 | $4.83 | $57K |
| 99204 Office E&M - New | Office | 435 | 435 | $112.23 | $49K |
| 99213 Office E&M - Established | Office | 342 | 273 | $56.25 | $19K |
| 99214 Office E&M - Established | Office | 173 | 144 | $88.59 | $15K |
| 95886 Electrical Nerve Conductivity | Office | 163 | 86 | $69.53 | $11K |
| 36415 Venipuncture Blood Collection | Office | 138 | 132 | $8.47 | $1,169 |
| 95911 Electrical Nerve Conductivity | Office | 114 | 114 | $146.43 | $17K |
| 64615 Musculoskeletal | Office | 45 | 18 | $107.96 | $4,858 |
| 95816 Neurologic | Office | 44 | 44 | $282.55 | $12K |
| 95909 Electrical Nerve Conductivity | Office | 13 | 12 | $82.72 | $1,075 |
By year: 2022 $185K for 12,150 services; 2023 $196K for 12,292 services; 2024 $195K for 13,426 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 138 | 132 | $8.47 | $1,169 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark K Lencke prescribed most often to Medicare patients was Donepezil Hcl, with 380 prescriptions and refills. In total Mark K Lencke wrote 2,929 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Donepezil Hcl Generic | 380 | 677 | 113 | $4,348 |
| Memantine Hcl Generic | 315 | 473 | 82 | $9,746 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 206 | 428 | 59 | $6,248 |
| Levetiracetam Generic | 170 | 325 | 52 | $7,016 |
| Primidone Generic | 151 | 277 | 34 | $3,536 |
| Gabapentin Generic | 103 | 137 | 33 | $1,715 |
| Topiramate Generic | 87 | 143 | 20 | $1,234 |
| Lacosamide Generic | 83 | 83 | 16 | $5,715 |
| Pyridostigmine Bromide Generic | 82 | 170 | 20 | $7,567 |
| Amitriptyline Hcl Generic | 76 | 123 | 20 | $711 |
| Rizatriptan Rizatriptan Benzoate | 60 | 62 | 18 | $603 |
| Rasagiline Mesylate Generic | 49 | 95 | 12 | $5,530 |
| Tizanidine Hcl Generic | 48 | 58 | 19 | $161 |
| Sumatriptan Succinate Generic | 44 | 44 | 14 | $2,582 |
| Pregabalin Generic | 44 | 55 | 13 | $621 |
Brand drugs: 313 claims; generic drugs: 2,603 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark K Lencke $2,118 ($2,118 in general payments such as food, travel and fees) from 30 companies. The largest payer was Abbvie Inc. with $426.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 24 | $426 |
| EMD Serono, Inc. MRK.DE | 4 | $133 |
| TG Therapeutics, Inc. TGTX | 5 | $133 |
| Lundbeck LLC | 4 | $115 |
| Pfizer Inc. PFE | 6 | $112 |
| UCB, Inc. UCB.BR | 4 | $109 |
| ACADIA Pharmaceuticals Inc ACAD | 4 | $108 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $88.35 |
| Neurocrine BioSciences, Inc. NBIX | 3 | $86.35 |
| Catalyst Pharmaceuticals, Inc. CPRX | 3 | $70.45 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.